EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?

Rossella Fasano, Simona Serratì iD, Tania Rafaschieri, Vito Longo, Roberta Di Fonte, Letizia Porcelli, Amalia Azzariti iD

Biomolecules · 2024

DOI: 10.3390/biom14040396 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Rossella Fasano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Immunotherapy, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small-cell lung cancer (SCLC) cases represent approximately 15% of all lung cancer cases, remaining a recalcitrant malignancy with poor survival and few treatment options. In the last few years, the addition of immunotherapy to chemotherapy improved clinical outcomes compared to chemotherapy alone, resulting in the current standard of care for SCLC. However, the advantage of immunotherapy only applies to a few SCLC patients, and predictive biomarkers selection are lacking for SCLC. In particular, due to some features of SCLC, such as high heterogeneity, elevated cell plasticity, and low-quality tissue samples, SCLC biopsies cannot be used as biomarkers. Therefore, the characterization of the tumor and, subsequently, the selection of an appropriate therapeutic combination may benefit greatly from liquid biopsy. Soluble factors, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) are now useful tools in the characterization of SCLC. This review summarizes the most recent data on biomarkers detectable with liquid biopsy, emphasizing their role in supporting tumor detection and their potential role in SCLC treatment choice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsImmunotherapyBiomarkers, TumorNeoplastic Cells, CirculatingHumansLiquid BiopsyCirculating Tumor DNAExtracellular Vesicles

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)circulating tumor cells (CTCs)extracellular vesicles (EVs)immunotherapysmall-cell lung cancer (SCLC)soluble factors

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy.
  • Medical Thoracic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.

ORCID-Profile: Simona Serratì, Amalia Azzariti

Zitieren

APA

Fasano, R., Serratì, S., Rafaschieri, T., Longo, V., Di Fonte, R., Porcelli, L., & Azzariti, A. (2024). Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?. Biomolecules. https://doi.org/10.3390/biom14040396

Vancouver

Fasano R, Serratì S, Rafaschieri T, Longo V, Di Fonte R, Porcelli L, et al. Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?. Biomolecules. 2024. doi:10.3390/biom14040396

BibTeX
@article{Fasano2024,
  author = {Fasano, Rossella and Serratì, Simona and Rafaschieri, Tania and Longo, Vito and Di Fonte, Roberta and Porcelli, Letizia and Azzariti, Amalia},
  title = {Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14040396}
}
Kostenlos starten →